關(guān)鍵詞： 拜耳 Steigerwald
2013年5月17日訊 /生物谷BIOON/ --拜耳（Bayer）日前宣布，已與德國中草藥制造商Steigerwald Arzneimittelwerk GmbH簽署了一項(xiàng)協(xié)議,，收購該公司100%股份,。Steigerwald位于德國達(dá)姆施塔特,，是一家私人控股的制藥公司，專門研究、開發(fā),、生產(chǎn)高質(zhì)量中草藥,，其產(chǎn)品包括Iberogast和Laif，前者為功能性胃腸病藥物,，后者為中度至重度抑郁癥治療藥物,。
此次收購的相關(guān)財(cái)務(wù)細(xì)節(jié)尚未披露。在完成反壟斷審查后,，該筆交易預(yù)計(jì)將于2013年7月初完成,。
“此次收購是加強(qiáng)保健消費(fèi)品業(yè)務(wù)的戰(zhàn)略舉措，將擴(kuò)大我們在胃腸功能紊亂治療領(lǐng)域的產(chǎn)品組合,，使我們有體會(huì)提升在德國,、快速增長的東歐及中歐地區(qū)、獨(dú)聯(lián)體國家的存在感,，”拜耳首席執(zhí)行官M(fèi)arijn Dekkers博士說道,。
Steigerwald股東之一Klaus Moller稱：“作為一個(gè)家族企業(yè)，我們?yōu)樽陨碓谂嘤烷_發(fā)我們品牌方面所取得的成績感到驕傲,。我們相信,，拜耳通過其廣泛的市場推廣、銷售,、分銷及研究專長,，能夠?qū)⑽覀兯〉贸晒μ嵘揭粋€(gè)新的高度。”
Steigerwald在2012年的銷售收入為6130萬歐元,，目前該公司員工總數(shù)約180人,，拜耳將接管Steigerwald的員工，其總部,、生產(chǎn)基地及銷售機(jī)構(gòu)將保留現(xiàn)有的結(jié)構(gòu),。（Darmstadt）（生物谷Bioon.com）
英文原文：Bayer to acquire Steigerwald Arzneimittelwerk GmbH
Transaction includes Iberogast? and Laif? brands
Leverkusen, Germany, May 16, 2013 – Bayer signed an agreement Thursday to acquire 100% of the shares of Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany, a privately held pharmaceutical company specializing in pharmacy-only herbal medicines. Steigerwald’s product portfolio includes Iberogast? for the treatment of functional gastrointestinal disorders and Laif? for the treatment of mild to moderate depression. Financial details have not been disclosed. The transaction is subject to fulfillment of the usual conditions, including antitrust clearance, and is expected to close at the beginning of July 2013.
“This transaction is further evidence of our commitment to augment organic growth with strategic bolt-on acquisitions. It will allow us to provide consumers with an even broader range of self-care options,” said Dr. Marijn Dekkers, CEO of Bayer AG. “This acquisition broadens our product offering for the treatment of gastrointestinal disorders and gives us the opportunity to enhance our presence in Germany, the fast-growing regions of East-Central Europe, and the CIS countries.”
Klaus M?ller, one of Steigerwald’s shareholders, added: “As a family-owned business, we take great pride in what we have achieved in nurturing and developing our brands. We believe that Bayer, with its extensive marketing, sales, distribution and research expertise, is well positioned to take our success to the next level.”
Steigerwald generated sales of EUR 61.3 million in 2012. The company employs approximately 180 people and has its headquarters and manufacturing site in Darmstadt. Bayer has committed to take over all of Steigerwald’s employees. The Darmstadt site and the sales organization are to retain their existing structures.
(責(zé)任編輯：lili.zhao)
